Evaluation of antineuraminidase antibody in preclinical and clinical studies of seasonal trivalent live influenza vaccine


Antibodies to influenza virus neuraminidase (NA) is one of the factors for protection against influenza infection. The aim of the study was to evaluate homologous and heterologous antibody to influenza virus NA after immunization of volunteers with trivalent seasonal live influenza vaccine (LAIV) in the fall 2005. Anti-NA antibody response was estimated using NA inhibition test (N1) in fetuin coated microplates with reassortants based on A/equine/Prague/1/56(H7N7) influenza virus and containing N1 of different origin. Before immunization 16,1 % of 56 volunteers had antibody titers > 1:20 to NA of avian A(H5N1 ) influenza virus and 7,1% - to pandemic A(H1N1) of 2009 year. Immunization with LAIV result in statistically significant increased titers of N1 antibody only to seasonal A(H1N1) influenza virus and induced little cross-reactive antibody response to 2009 A(H1N1) or avian A(H5N1 ) influenza virus. The immune response to homologous NA was not dependent on anti-HA antibody levels before immunization.

Full Text

Restricted Access

About the authors

T A Smolonogina

Institute of Experimental Medicine of the Northwest Branch of Russian Academy of Medical Sciences, St. Petersburg

Email: smolonogina@mail.ru

Yu A Desheva

Institute of Experimental Medicine of the Northwest Branch of Russian Academy of Medical Sciences, St. Petersburg

N E Gorev

Research Institute of Influenza, Ministry health and social development of the Russian Federation, St. Petersburg

L G Rudenko

Institute of Experimental Medicine of the Northwest Branch of Russian Academy of Medical Sciences, St. Petersburg


  1. Александрова Г.И. Применение метода генетической рекомбинации для получения вакцинных штаммов вируса гриппа // Вопр. вирусол. 1977. № 4. С. 387-395.
  2. Дешева Ю.А., Руденко Л.Г., Смолоногина Т.А. и др. Реассортантный штамм вируса гриппа RN1-swine A(H7N1) для определения антител к нейраминидазе при гриппозной инфекции и вакцинации // Заявка на изобретение № 2010 125 452/10 (036151) от 21.06.2010, положительное решение о выдаче патента от 16.03.2011.
  3. Киселева И.В., Руденко Л.Г., Александрова Г.И. и др. Вакцинный штамм вируса гриппа A/17/Новая Каледония/99/145(Н1N1 ) для производства живой гриппозной интраназальной вакцины для взрослых // Патент № 2183672, опубл. 20.06.02.
  4. Ларионова Н.В., Киселева И.В., Руденко Л.Г. и др. Вакцинный штамм вируса гриппа A/17/Калифорния/2009/38 (H1N1) для производства живой гриппозной интраназальной вакцины для взрослых и детей // Заявка на изобретение № 2009 134769, дата приема 16.09.09.
  5. Найхин А.Н., Царицына И.М., Олейникова Е.В и др. Формирование и защитные функции антител к нейраминидазе вируса гриппа А // Вопр. вирусол. 1985. № 1. С. 35-39.
  6. Bosch B.J., Bodewes R., de Vries R.P. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets // J. Virology. 2010. Vol. 84. № 19. P. 10366-10374.
  7. Brett 1.С., Johansson B.E. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system // Virology. 2005. Vol. 339. № 2. P. 273-280.
  8. Garten R.J., Davis C.T., Russell C.A. et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans // Science. 2009. Vol. 325. № 5937. P. 197-201.
  9. Gaydos J.C., Top F.H. Jr, Hoddcr R.A. et al. Swine influenza A outbreak, Fort Dix, New Jersey, 1976 // Emerg. Infect. Dis. 2006. Vol. 12. P. 23-28.
  10. Kendal A.P., Pereira M.S., Skehel J. Concepts and procedures for laboratory-based Influenza surveillance // Centers for Disease Control, Atlanta. 1982. P. B17-B22.
  11. Kumar S., Tamura K., Jakobsen I.B. et al. MEGA2: molecular evolutionary genetics analysis software // Bioinformatics. 2001. Vol. 17. № 12. P. 1244-1245.
  12. Lambré C.R., Terzidis H., Greffard A. et al. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates // J. of Immunological Methods. 1990. Vol. 135. P. 49-57.
  13. Nicholas K.B., Nicholas H.B. Jr, Deerfield D.W. GeneDoc: analysis and visualization of genetic variation // EMBNEW News. 1997. Vol. 4. P. 14.
  14. Pichyangkul S., Jongkaewwattana A., Thitithanyanont A. et al. Cross-reactive Antibodies against avian influenza virus A (H5N1) // Emerg. Infect. Dis. 2009. Vol. 15. №9. P. 1537-1539.
  15. World Health Organization (2011). Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5NI) Reported to WHO. Available: http://www. who.int/csr/disease/avian_influenza/country/cases_table_201 l_04_01/en/indcx.html
  16. Sandbulte M.R., Jimenez G.S., Boon A.C. et al. Crossreactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans // PLoS Medicine. 2007. Vol. 4. № 2. P. 265-272.
  17. Gallagher M., Bucher D.J., Dourmashkin R. et al. Isolation of immunogenic neuraminidases of human influenza viruses by a combination of genetic and biochemical procedures // J. of Clin. Microbiol. 1984. Vol. 20. Ks 1. P. 89-93.



Abstract - 73


Article Metrics

Metrics Loading ...




  • There are currently no refbacks.

Copyright (c) 2011 Smolonogina T.A., Desheva Y.A., Gorev N.E., Rudenko L.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies